弥漫性大B细胞淋巴瘤的国际预后指数:IPI、R-IPI与NCCN-IPI的比较
研究纳入7项多中心随机临床试验中1998至2009年接受一线R-CHOP(或变体)治疗的2124例DLBCL患者,比较IPI、R-IPI与NCCN-IPI对总生存(OS)的区分能力。NCCN-IPI高低危组间OS绝对差最大,区分OS最佳(一致性指数0.632 vs 0.626[IPI] vs 0.590[R-IPI])。
要点
- NCCN-IPI区分OS优于IPI和R-IPI,一致性指数0.632 vs 0.626 vs 0.590
- NCCN-IPI高危与低危组间5年OS估计差最大,为49%至92%
- 利妥昔单抗时代各临床评分均未识别出长期生存明确低于50%的亚组
核心结论
- 总体上NCCN-IPI表现优于IPI和R-IPI,其高危与低危组间OS估计绝对差最大且区分OS最佳,一致性指数0.632 vs 0.626(IPI)vs 0.590(R-IPI)。
- NCCN-IPI低危患者生存结局良好,进一步改善空间很小。
- 利妥昔单抗时代,没有临床风险评分能识别出长期生存明确低于50%的患者亚组。
- 将肿瘤和微环境的分子特征整合进NCCN-IPI或IPI,可能更好地界定最需要新治疗策略的高危组。
研究设计与样本
- 评估1998年至2009年在7项多中心随机临床试验中接受一线利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松(R-CHOP;或变体)治疗的2124例DLBCL患者。
- 中位年龄63岁,56%的患者为男性。
- 比较IPI、R-IPI和NCCN-IPI三种纳入简单临床参数(年龄、乳酸脱氢酶、受累数量/部位、分期、体能状态)的评分系统对总生存(OS)的区分能力。
主要发现
- 5年OS估计:IPI为54%至88%,R-IPI为61%至93%,NCCN-IPI为49%至92%。
- NCCN-IPI高危与低危组间OS估计绝对差最大,区分OS最佳(一致性指数=0.632 vs 0.626[IPI] vs 0.590[R-IPI])。
- 在每个给定的IPI风险类别内,NCCN-IPI风险类别与OS显著相关(P ≤ .01);反之不成立。
- IPI在所有NCCN-IPI风险类别内均未提供额外的显著预后信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Great heterogeneity in survival exists for patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL). Three scoring systems incorporating simple clinical parameters (age, lactate dehydrogenase, number/sites of involvement, stage, performance status) are widely used: the International Prognostic Index (IPI), revised IPI (R-IPI), and National Comprehensive Cancer Network IPI (NCCN-IPI). We evaluated 2124 DLBCL patients treated from 1998 to 2009 with frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; or variant) across 7 multicenter randomized clinical trials to determine which scoring system best discriminates overall survival (OS). Median age was 63 years, and 56% of patients were male. Five-year OS estimates ranged from 54% to 88%, from 61% to 93%, and from 49% to 92% using the IPI, R-IPI, and NCCN-IPI, respectively. The NCCN-IPI had the greatest absolute difference in OS estimates between the highest- and lowest-risk groups and best discriminated OS (concordance index = 0.632 vs 0.626 [IPI] vs 0.590 [R-IPI]). For each given IPI risk category, NCCN-IPI risk categories were significantly associated with OS (P ≤ .01); the reverse was not true, and the IPI did not provide additional significant prognostic information within all NCCN-IPI risk categories. Collectively, the NCCN-IPI outperformed the IPI and R-IPI. Patients with low-risk NCCN-IPI had favorable survival outcomes with little room for further improvement. In the rituximab era, none of the clinical risk scores identified a patient subgroup with long-term survival clearly <50%. Integrating molecular features of the tumor and microenvironment into the NCCN-IPI or IPI might better characterize a high-risk group for which novel treatment approaches are most needed.
引用
- Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020. PMID: 32232482. doi:10.1182/blood.2019002729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。